Boston Scientific Corporation (BSX) SVP Maulik Nanavaty Sells 15,568 Shares

Boston Scientific Corporation (NYSE:BSX) SVP Maulik Nanavaty sold 15,568 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $25.38, for a total value of $395,115.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Boston Scientific Corporation (NYSE BSX) traded up $0.26 on Monday, reaching $26.18. The company’s stock had a trading volume of 8,449,845 shares, compared to its average volume of 10,008,726. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $35,590.00, a P/E ratio of 374.00, a price-to-earnings-growth ratio of 1.88 and a beta of 0.81. Boston Scientific Corporation has a one year low of $23.29 and a one year high of $29.93.

Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.34. The company had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. Boston Scientific’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 earnings per share. equities analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quadrature Capital Ltd purchased a new stake in Boston Scientific during the fourth quarter worth $1,011,000. Eaton Vance Management boosted its position in Boston Scientific by 36.6% during the fourth quarter. Eaton Vance Management now owns 4,612,840 shares of the medical equipment provider’s stock worth $114,352,000 after purchasing an additional 1,235,921 shares in the last quarter. OppenheimerFunds Inc. boosted its position in Boston Scientific by 11.5% during the fourth quarter. OppenheimerFunds Inc. now owns 7,976,540 shares of the medical equipment provider’s stock worth $197,739,000 after purchasing an additional 824,195 shares in the last quarter. State of Tennessee Treasury Department lifted its position in shares of Boston Scientific by 110.6% in the fourth quarter. State of Tennessee Treasury Department now owns 2,307,840 shares of the medical equipment provider’s stock valued at $57,211,000 after acquiring an additional 1,211,859 shares in the last quarter. Finally, Timber Hill LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $1,319,000. Institutional investors own 89.84% of the company’s stock.

A number of brokerages recently weighed in on BSX. Canaccord Genuity began coverage on Boston Scientific in a report on Tuesday, October 24th. They set a “buy” rating and a $36.00 price objective on the stock. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Friday, October 20th. BMO Capital Markets upped their price objective on Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. SunTrust Banks set a $34.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, Barclays reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $31.00.

ILLEGAL ACTIVITY WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/12/boston-scientific-corporation-bsx-svp-maulik-nanavaty-sells-15568-shares.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit